Table 2 Complement therapeutics for adult kidney diseases
From: Molecular mechanisms and therapeutic interventions in acute kidney injury: a literature review
Name | Target | Disease | Status | NCT |
|---|---|---|---|---|
Eculizumab | C5 | anti-GBM | Phase 2 | NCT06513338 |
ANCA-Associated Vasculitis | Phase 2 | NCT01275287 | ||
MPGN | Phase 2 | NCT02093533 | ||
CCX168 (Avacopan) | C5a receptor | ANCA-Associated Vasculitis | Phase 3 | NCT02994927 |
IgAN | Phase 2 | NCT06676579 | ||
AMY-101 | C3 | Complement Mediated Diseases | Phase 1 | NCT03316521 |
Pegcetacoplan | C3 | C3G or IC-MPGN | Phase 3 | NCT05809531 |
LNP023 | C3a receptor | IgAN | Phase 2 | NCT03373461 |